admin

The Italian biotech Genenta Science has raised €13.2M in a private round to fund two ongoing phase I/II trials of its stem cell therapy Temferon for blood and brain cancer

A new state-of-the-art facility dedicated to plasmid manufacturing will be in operation by August 2019 in Gerenzano, Italy. The new site will couple with the existing GMP facility active in the Cell and Gene (C&G) therapy space. With 800m2 (8,000 square feet) of cleanrooms, the two facilities of Anemocyte, the first Biotech Manufacturing Organisation (BMO), will address manufacturing needs of Somatic Cells, Non-Viral Modified Cells, Vesicles and Plasmids for Viral Vectors

Cell and gene therapies could be flying high soon, joining the medical supplies, whole blood products, and even organs being transported by drones. In collaboration with RPS Aerospace, the Italy-based biotech company Anemocyte developed a remotely piloted drone system to securely transport final cell and gene therapy products from manufacturing sites to clinical centers

The discussion moves onto goes onto the fine line between success and failure, examining the stories of Apollo 13, Thomas Edison and Elizabeth Gilbert, the author of Eat. Pray. Love. Dwayne explores failure and its negative connotations. Failure provides an opportunity to learn and to display passion to others, it’s an iteration on the road to success. In the immortal words of the great Thomas Edison

With a swell of R&D activity flowing into the development of cell and gene therapies over the past decade, a manufacturing shortage gripped the industry. This caused industry participants to express grave fears that the manufacturing shortage would threaten industry growth and lengthen time-to-market for these new types of living therapies

È di pochi giorni fa la notizia dell’approvazione negli Stati Uniti di una terapia genica per l’atrofia muscolare spinale

Bluebird Bio Inc.’s first gene therapy, a treatment for an inherited blood disorder, was cleared by European Union regulators, another milestone for the field following U.S. approval of Novartis AG’s $2.1 million treatment for a lethal childhood disease

A comprehensive guide to Europe’s growing advanced therapies and viral vector manufacturing landscape

CRO, CMO, CDMO. These acronyms are well known in the biotech and pharma industry. But what is a BMO? If you haven’t heard of it, don’t worry. After all, there is only one BMO worldwide. We have set out to discover more about it, this biotech manufacturing organization

L’Italia come Hub internazionale per le terapie avanzate. Uno scenario di sfide e opportunitá